Table 1.
Patient no. | Gender | Age (years) | Stage | Metastasis | Chemotherapy | TRT before PET 2 | EORTC response | PERCIST response | Progression-free survival (days) | Overall survival (days) | Death |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 80 | LD | NM | CP | x | PMR | PMR | 340 | 424 | – |
2 | F | 61 | ED | B | EP | – | PMR | PMR | 360 | 420 | – |
3 | M | 65 | LD | NM | EP | – | PMD | PMD | 88 | 307 | x |
4 | M | 62 | ED | NM, L, B, A | EP | – | SMD | SMD | 198 | 198 | – |
5 | M | 62 | ED | NM, L, B | EP | – | PMR | PMR | 188 | 408 | x |
6 | M | 48 | ED | NM, L, B | EP | – | PMD | PMD | 224 | 329 | – |
7 | M | 57 | LD | B | EP | x | CMR | CMR | 381 | 675 | x |
8 | M | 52 | LD | NM | EP | x | PMR | PMR | 328 | 500 | x |
9 | F | 60 | ED | NM, L, B | EP | – | SMD | SMD | 202 | 225 | x |
10 | F | 55 | ED | NM | EP | – | PMR | PMR | 160 | 160 | – |
11 | M | 66 | LD | NM | CAV | x | PMD | PMD | 79 | 162 | x |
12 | M | 66 | LD | – | CP | x | PMD | PMD | 160 | 347 | – |
13 | M | 54 | LD | NM | EP | x | PMR | PMR | 1028 | 1566 | – |
14 | F | 51 | LD | – | EP | x | SMD | SMD | 1363 | 1363 | – |
15 | M | 71 | LD | NM | EP | x | SMD | SMD | 360 | 1163 | x |
16 | F | 76 | ED | A | EP | – | PMR | PMR | 265 | 265 | – |
17 | M | 51 | LD | – | EP | x | CMR | CMR | 1241 | 1241 | – |
18 | M | 59 | LD | – | EP | x | CMR | CMR | 1386 | 1386 | – |
19 | M | 43 | LD | – | CP | x | CMR | CMR | 513 | 590 | x |
20 | M | 76 | LD | – | EP | x | CMR | CMR | 1344 | 1344 | – |
21 | F | 61 | ED | A | EP | x | PMD | PMD | 234 | 711 | x |
22 | F | 48 | LD | – | EP | x | CMR | CMR | 260 | 260 | – |
23 | M | 52 | ED | NM, L, B | EP | – | PMD | PMD | 158 | 201 | x |
24 | M | 69 | ED | L, B | EP | – | SMD | SMD | 167 | 251 | – |
25 | F | 51 | ED | B | EP | – | PMR | PMR | 151 | 405 | x |
26 | M | 55 | LD | NM | EP | x | PMD | PMD | 264 | 557 | – |
27 | M | 51 | LD | – | EP | x | CMR | CMR | 1615 | 1615 | – |
28 | F | 62 | ED | L | EP | x | CMR | CMR | 465 | 1149 | – |
29 | F | 65 | ED | NM, L | CAV | x | PMR | PMR | 209 | 408 | x |
A, adrenal gland; B, bone; NM, nodal metastasis; L, liver; EP, etoposide and cisplatin; CAV, cyclophosphamide, adriamycin and vincristine; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease.